 Aditxt Incs NASDAQ: ADTX therapeutic program Adimune has completed a toxicology study indicating a favorable safety profile of ADI-100 for rejection of transplanted organs, skin allografting, autoimmune diseases, and allergies. The company says the completion of preclinical. 